AUTL
Closed
Autolus Therapeutics Ltd
2.29
+0.01 (+0.44%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 2.28
Day's Range: 2.195 - 2.34
Send
sign up or login to leave a comment!
When Written:
1.84
Autolus Therapeutics Ltd is a clinical-stage biopharmaceutical company that specializes in developing next-generation, programmed T-cell therapies for the treatment of cancer. The company was founded in 2014 and is headquartered in London, United Kingdom. Autolus’ proprietary technology platform uses advanced cell engineering techniques to create T-cells that are programmed to recognize and attack cancer cells.
Autolus’ lead product candidate, AUTO1, is a CAR T-cell therapy that is being developed for the treatment of acute lymphoblastic leukemia (ALL). The company is also developing several other CAR T-cell therapies for the treatment of other types of cancer, including lymphoma and solid tumors.
Autolus has partnerships with several leading pharmaceutical companies, including Moderna, Inc. and AstraZeneca plc, to develop and commercialize its T-cell therapies. The company has raised over $300 million in funding to date from investors such as Syncona, Woodford Investment Management, and the Wellcome Trust.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Autolus’ lead product candidate, AUTO1, is a CAR T-cell therapy that is being developed for the treatment of acute lymphoblastic leukemia (ALL). The company is also developing several other CAR T-cell therapies for the treatment of other types of cancer, including lymphoma and solid tumors.
Autolus has partnerships with several leading pharmaceutical companies, including Moderna, Inc. and AstraZeneca plc, to develop and commercialize its T-cell therapies. The company has raised over $300 million in funding to date from investors such as Syncona, Woodford Investment Management, and the Wellcome Trust.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!